RET and cancer: In the metanalysis reported by Kohno [18], RET fusions were found in 0.7% of total samples, including cancers other than thyroid and lung ones, such as breast (0.00%–0.21%), colon (0.00%–0.26%), esophageal (0.00%–0.17%), ovarian (0.00%–0.17%), prostate (0.08%), and stomach (0.81%) carcinoma, as well as acute myeloid leukemia (0.00%–0.50%) and very rare cancers such as anaplastic ganglioglioma (a rare CNS tumor of children and young adults), and Erdheim–Chester Disease (a rare form of non-Langerhans cells histiocytosis).